STOCK TITAN

OraSure Technologies Inc - OSUR STOCK NEWS

Welcome to our dedicated page for OraSure Technologies news (Ticker: OSUR), a resource for investors and traders seeking the latest updates and insights on OraSure Technologies stock.

OraSure Technologies Inc., based in Bethlehem, Pennsylvania, is a pioneering medical devices company specializing in the development, manufacture, and distribution of oral fluid diagnostic and collection devices. As a leader in this field, OraSure offers a range of products designed to detect or diagnose critical medical conditions. The company operates through two primary segments: Diagnostics and Molecular Solutions.

In the Diagnostics segment, OraSure produces rapid oral diagnostic tests and specimen collection devices for infectious diseases, such as HIV and HCV. Notable products include the OraQuick® In-Home HIV Test, OraQuick Advance® Rapid HIV-1/2 Antibody Test, and the OraSure® HIV-1 Oral Specimen Collection Device. Additionally, the company offers the OraQuick® HCV Rapid Antibody Test, and various oral fluid testing solutions for drug abuse, such as the Intercept® Oral Fluid Drug Testing System and the Q.E.D.® Saliva Alcohol Test.

The Molecular Solutions segment focuses on kits used to collect, stabilize, and transport genetic material samples for molecular testing. These kits are essential for diagnosing hereditary diseases and infectious diseases, including COVID-19. The molecular solutions segment is a significant revenue driver for OraSure, with a substantial portion of sales originating from customers in the United States.

Beyond diagnostics, OraSure also manufactures and sells cryosurgical products like Histofreezer®, used for the cryosurgical removal of common and plantar warts, along with other benign skin lesions. These products are available both for professional physician office markets and over-the-counter use.

Recently, OraSure has announced its third-quarter 2023 financial results and certain business developments. Notably, the regular earnings conference call is scheduled for November 7, 2023. This announcement signifies the company's commitment to transparency and continuous communication with its stakeholders.

Rhea-AI Summary
OraSure Technologies, Inc. (NASDAQ: OSUR) will announce its first-quarter 2024 financial results and host an earnings call on May 8th, 2024. The conference call will cover financial results and business developments, with a webcast available on OraSure's investor relations page. Participants can pre-register for the live call via a provided link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
-
Rhea-AI Summary
NOWDiagnostics (NOWDx) appoints Dr. Stephen S. Tang, former head of OraSure Technologies, as the chairman of the board. Dr. Tang brings extensive experience in the medical diagnostic industry, having led OraSure Technologies to significant growth and product development during his tenure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.76%
Tags
none
-
Rhea-AI Summary
OraSure Technologies, Inc. (OSUR) reported Q4 GAAP EPS of $0.27 and Q4 Non-GAAP EPS of $0.22. The company's cash balance grew to $290.4 million as of December 31, 2023. OraSure entered the U.S. Syphilis testing market through a strategic distribution agreement with Diagnostics Direct. The company highlighted progress in operational cash flow and margin expansion, aiming for break-even in cash flow from operations for the core business by the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.96%
Tags
none
Rhea-AI Summary
OraSure Technologies, Inc. (OSUR) will hold its earnings conference call for Q4 2023 financial results and business updates on Feb. 27, 2024, at 5 p.m. ET. The webcast will be available on the company's investor relations page. Participants can register in advance for access.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
-
Rhea-AI Summary
OraSure Technologies, Inc. (NASDAQ: OSUR) expands innovation pipeline and revenue growth through strategic partnership with Sapphiros, a consumer diagnostics portfolio company. OraSure leads Series B financing and secures exclusive distribution rights to key products in Sapphiros' development pipeline, aligning with OraSure's areas of expertise. Initial product distribution expected in 2024, with accelerated revenue growth anticipated beginning in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.12%
Tags
none
-
Rhea-AI Summary
OraSure Technologies, Inc. (NASDAQ: OSUR) announces participation in investor conferences. Live webcasts and replays available on the company's investor relations page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
conferences
Rhea-AI Summary
OraSure Technologies, Inc. (NASDAQ: OSUR) Announces Q3 GAAP EPS of $0.15 and Q3 Non-GAAP EPS of $0.27, Grows Cash Balance to $224.9M, Reports 7% Core Revenue Growth, and Provides Financial Guidance
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.96%
Tags
none
-
Rhea-AI Summary
OraSure Technologies, Inc. has scheduled its regular earnings conference call for November 7, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
-
Rhea-AI Summary
OraSure Technologies, Inc. announces Q2 2023 financial results, with InteliSwab® test revenue of $47.5 million, a 10% YoY increase. Q2 core revenue grew 4% sequentially and 3% YoY. Cash balance increased to $185.9 million. InteliSwab® orders expected to generate at least $70 million in revenue in H2 2023. On track to achieve operating cash flow breakeven on core business by end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.29%
Tags
none
Rhea-AI Summary
OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call for 5:00 pm ET on Thursday, August 3, 2023. A webcast of the conference call will be available on OraSure's website. The webcast will be archived for approximately 90 days. To participate in the live conference call, pre-registration is required.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags

FAQ

What is the current stock price of OraSure Technologies (OSUR)?

The current stock price of OraSure Technologies (OSUR) is $3.665 as of December 20, 2024.

What is the market cap of OraSure Technologies (OSUR)?

The market cap of OraSure Technologies (OSUR) is approximately 272.3M.

What does OraSure Technologies Inc. specialize in?

OraSure Technologies Inc. specializes in the development, manufacture, and distribution of oral fluid diagnostic and collection devices.

Where is OraSure Technologies Inc. headquartered?

OraSure Technologies Inc. is headquartered in Bethlehem, Pennsylvania.

What are the main segments of OraSure's business?

The main segments are Diagnostics and Molecular Solutions.

What products are included in OraSure's Diagnostics segment?

The Diagnostics segment includes rapid oral diagnostic tests for HIV and HCV, and oral fluid testing solutions for drug abuse.

What are some notable products of OraSure Technologies?

Notable products include OraQuick® In-Home HIV Test, OraQuick Advance® Rapid HIV-1/2 Antibody Test, and Histofreezer®.

What does the Molecular Solutions segment focus on?

The Molecular Solutions segment focuses on kits for collecting, stabilizing, and transporting genetic material samples for molecular testing.

How does OraSure contribute to COVID-19 testing?

OraSure provides molecular solutions that include kits for the collection and transport of samples used in COVID-19 molecular testing.

What are cryosurgical products offered by OraSure?

Cryosurgical products include Histofreezer® for the removal of warts and other benign skin lesions.

When is OraSure's next earnings conference call?

The next earnings conference call is scheduled for November 7, 2023.

Where can I find OraSure's financial reports?

OraSure's financial reports can be found on their official website under the GAAP to Non-GAAP Reconciliation section.

OraSure Technologies Inc

Nasdaq:OSUR

OSUR Rankings

OSUR Stock Data

272.27M
72.22M
3.05%
91.59%
1.48%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
BETHLEHEM